Docs
All documentation Fundamental API Live (Delayed) API EOD Historical API Intraday API Real-Time (websockets) API Google Sheets add-on Excel add-on
Community
Academy 134 articles Forum Github 13 repos
Marketplace
Spreadsheets
Google Sheets add-on Excel add-on Wordpress plugin
Pricing
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. NASDAQ /
  3. OLMA.NASDAQ

Olema Pharmaceuticals Inc (OLMA NASDAQ) stock market data APIs

$15 -0.43(-2.8%) as of July 26, 2024
Price chart is built with Anychart

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Olema Pharmaceuticals Inc Financial Data Overview

15.43
15
-
15.51
14.63
7.78-17.791
822 M
55 934 K
0
-0.56
2.07
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'OLMA',
Type: 'Common Stock',
Name: 'Olema Pharmaceuticals Inc',
Exchange: 'NASDAQ',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG00T5JMRT4',
ISIN: NULL,
CUSIP: NULL,
CIK: '1750284',
EmployerIdNumber: NULL,
FiscalYearEnd: 'December',
IPODate: '2020-11-19',
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Biotechnology',
HomeCategory: NULL,
IsDelisted: false,
}

Olema Pharmaceuticals Inc Fundamental Data is available in our Financial Data APIs

  • Net Revenue 0
  • EBITDA -112 133 000
  • Earnings Per Share -2
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Olema Pharmaceuticals Inc Earnings via APIs

  • Latest Release 2024-05-08
  • EPS/Forecast -0.55

Get Olema Pharmaceuticals Inc End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Olema Pharmaceuticals Inc latest news via APIs

15 Small-Cap Stocks with High Potential

In this article, we will take a look at the 15 small-cap stocks with high potential. To skip our analysis of the latest trends, and market activity, you can go directly to see the 5 Small-Cap Stocks w...

Olema Oncology Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate

Olema Oncology OP-3136 demonstrated potent anti-tumor activity alone and in combination with both palazestrant and CDK4/6 inhibitors in preclinical ER+ breast cancer models Initiating IND-enabling s...
Do you have any questions?
support@eodhistoricaldata.com